The article analyses Section 3(d) of India’s Patents Act and its controversial role in pharmaceutical patents post-Novartis. It examines its origins, connection to EU SPCs, and the focus on preventing evergreening by emphasising enhanced efficacy.
Read more about Examining the Origins of Section 3(d) in India’s Patents Act and Its Connection to EU SPCsTag: Pharmaceutical patents
Revisiting Supplementary Protection Certificates of the European Union
The article examines the structure and implications of supplementary protection certificates in the European Union. It reviews their regulatory evolution, procedural requirements, and influence on pharmaceutical market exclusivity, while also considering comparative perspectives from India.
Read more about Revisiting Supplementary Protection Certificates of the European UnionProfiting from the Patent Cliff: What Drug Manufacturers Need to Know about Secondary Patents
This post explores how drug manufacturers leverage secondary patents to manage the patent cliff and maintain exclusivity. A detailed analysis of Entresto’s patent timeline and Indian legal context is provided.
Read more about Profiting from the Patent Cliff: What Drug Manufacturers Need to Know about Secondary PatentsLatest Patent Cases in 2022 – Part 1
This post analyses recent Indian patent cases from 2022, focusing on notable court decisions such as MSN Laboratories v. Novartis Ag. It provides legal insights into patent infringement and injunctions in the pharmaceutical sector.
Read more about Latest Patent Cases in 2022 – Part 1Recap 2021- Indian Patent Case Laws
This post analyses major Indian patent case laws from 2021, with a focus on Delhi High Court decisions involving interim injunctions and pharmaceutical patents. It offers an objective summary of key judgments relevant to patent infringement and validity in India.
Read more about Recap 2021- Indian Patent Case LawsLatest Patent Cases in 2021 – Part 3
This article examines recent patent litigation before the Delhi High Court, highlighting cases involving Novartis and Sulphur Mills in 2021. It discusses key judicial findings on patent validity, scope, and interim injunctions in Indian pharmaceutical and agricultural sectors.
Read more about Latest Patent Cases in 2021 – Part 3Latest Patent Cases in 2021 – Part 2
This article summarises pivotal Delhi High Court decisions on patent disputes in 2021, particularly involving pharmaceutical products. The analysis covers interim injunctions and key arguments in Indian patent litigation.
Read more about Latest Patent Cases in 2021 – Part 2Latest Patent Cases in 2021 – Part 1
The H. Lundbeck A/S vs Symed Labs Limited case involved a pre-notice settlement of a patent dispute, with the Delhi High Court decreeing the suit on agreed terms. The settlement clarifies the scope of Section 107A use and sets compliance and reporting obligations for the defendant.
Read more about Latest Patent Cases in 2021 – Part 1Delhi High Court asks government to consider issuing compulsory licenses, World IP day 2021, a solemn affair this year, India – South Africa patent waiver proposal opposed again and more
The Delhi High Court has advised the government to consider compulsory licensing of COVID-19 treatments, reflecting the urgent need for wider access. This post also covers the global debate on patent waivers and the observance of World IP Day 2021, with a focus on recent legal and policy updates.
Read more about Delhi High Court asks government to consider issuing compulsory licenses, World IP day 2021, a solemn affair this year, India – South Africa patent waiver proposal opposed again and moreIndian Patent Cases and Judgments of 2020
A detailed review of major Indian patent cases and judgments from 2020, addressing core issues in patent opposition, litigation, and enforcement. The analysis offers insights into judicial trends and key legal standards shaping Indian patent law.
Read more about Indian Patent Cases and Judgments of 2020